Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


10 Approvals To Watch For In Early 2017

Executive Summary

Dupixent, Austedo, brigatinib and Olumiant are among a raft of new drug approvals expected in the first four months of the year. Here, with help from Informa Pharma's Biomedtracker, we take a look at 10 of the more interesting products looking close to reaching the market, some for the second time of asking.


Related Content

Ex-Pfizer Employee Overseeing Xeljanz Global Marketing Sued For Trade Secret Theft
Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia
Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key
Will Radius Health's Abaloparatide Data Do The Trick In Osteoporosis?
Meek To Drive M&A At Ipsen, Building On Two Major Launches
AstraZeneca's ZS-9 Timeline Hit By FDA Complete Response Letter
'Transformative' Dupilumab Set For Third Quarter Filing In Atopic Dermatitis
BioMarin's Cerliponase Alfa Data Support Mid-Year Submissions
New Japanese Data Bode Well For Shionogi’s OIC Drug
Pressure off Teva's CNS hopes as tardive dyskinesia drug succeeds


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts